Member Info for OAPK20

No need to read or post abuse if you’re not interested.

RV 86%, close +14% above overhang

5 buy blocks single session totalling 1,426,666 (largest count of coverage); zero sell blocks; 14.6x classified buy-dominance. • Buy block price escalation 2.67 → 2.70 → 2.80 → 2.85 → 2.88 = institutional laddering up across session.

Aggregate bid quality improving — JBER bid 2.10 → 2.50, PEEL 2.40 → 2.50, SING 2.20 → 2.60, CANA 2.40 → 2.60. All MMs defending higher prices on bid side.

TOTAL LARGE PRINT VOLUME = 1,676,666

Session Volume: 2,191,284

UNKNOWN PRINT VOLUME (ALL sizes): 258,798

UNKNOWN % OF SESSION: 11.81% → Tape reliable

4 unknown print clusters at 16:38:59 (150k @ 2.85 close-zone) raises potential auction window distribution.

BASE CASE (70%): Breakout follow-through confirmed. 5 buy blocks + 14.6x dominance + buy block price escalation + inside bid step-up + 24th close above overhang = unequivocal accumulation evidence.

COUNTER-CASE (30%): Ask-side widening signals potential exit-side fragility; 16:38:59 close zone unknown 150k requires monitoring; gap from close 2.85 to ask 3.00 exposes buyers to immediate negative mark tomorrow if ask not absorbed.

CONFIRMATION TRIGGER: Tomorrow close ≥2.85 sustained AND spread <8% AND additional buy block ≥150k.

INVALIDATION TRIGGER: Tomorrow close <2.70 / sell block ≥200k with close <2.75 / spread widening above 12% with bid pullback.

Yeah as much of a chance of that as someone holding a share and never taking a loss

😂Nailed on 10 bagger then

Https://markets.businessinsider.com/news/stocks/soundhound-ai-named-as-overall-leader-in-the-2026-isg-buyers-guide-for-conversational-ai-emerging-providers-1036238911?op=1

What’s the investment case for your wife still holding ?

Be good to see if more Premier League clubs get on board. Surprising that Championship and lower division clubs aren't onboarding yet.

https://sporttower.ai/about

Pretty much covers Team GB Olympic sports and Organisations.

https://sportandrecreation.org.uk/members/membership-directory

Cracking day. More to come.

Or a Yorkville

Wait till this lands. Good luck

Roll on assays

Use for 6 months then agreement to sell

Expansion in Germany via dual share listing and local language app In February, to tap into the highly active German private investor market, MedPal gained a secondary listing of its shares on the Open Market of the Frankfurt Stock Exchange under the ticker Z1N. By completing this dual listing the company sees the chance to expand its shareholder base and increase liquidity of the shares. In addition, MedPal is planning to launch its services in the German market, having launched a German- language version of its app. This is part of a first step towards a European growth strategy. Over the next six months, additional MedPal services will be launched in Germany, with the company attracted to the country’s rapidly growing digital health market which is expected to expand at a compound annual growth rate in excess of 20% through to 2030.

Forecasts

We see the 2026 financial year (to August) as a bedding in period given the initial set up of operations and considering that meaningful numbers only started being delivered in November 2025. For the year as a whole we expect further steady growth in NHS pharmacy items, with around 380,000 processed, and a rapid rise in income from Medpal.clinic from a base of zero. Total revenues for the year are expected at £6.22 million, with a net loss of £2.2 million reflecting initial set up expenses. In 2027 we see an almost break-even position being reached on total revenues of £44.61 million. We are looking for pharmacy items to grow almost fourfold to 1.5 million, delivering revenues of £14.68 million. In MedPal.clinic we are looking for a more dramatic rise in revenues from £2.4 million to £29.6 million as patient momentum builds and the effects of the company’s planned marketing campaign are realised. We see the first full year of profitability in 2028, with a net profit of £4.54 million on revenues of £92.78 million. Again, pharmacy items see good but more modest growth, doubling to just over 3 million, with revenues also doubling to £29.48 million. MedPal.clinic revenues are forecast to grow at a lower rate from the higher base, by 112% to £62.82 million. Beyond that, in 2029, our model show revenues of £150.4 million and net profits of £9.5 million as the company’s operational gearing starts to have a more marked effect on profits.

• Facilities and product lines expanded to meet rising demand Additional units at the company’s facility in Swaffham have been acquired, tripling its available floor space and enabling capacity for over 100,000 prescription items per month. Additional funds have been raised to increase and widen the product base, including with GLP-1 agonist drug Mounjaro after MedPal Limited was approved as an authorised purchaser of m Eli Lilly pharmaceutical products. Analysts at Grand View Research suggest that the UK prescription weight-loss medications market will grow at a CAGR of 24.85% up to 2033.

• Investment delivers rising revenues and prescription volumes In the first four months of operations total prescription items dispensed amounted to c.147,000, generating revenues in excess of £1.5 million. Average gross margins are running at a healthy c.33%, driven by the company’s efficient, technology-driven fulfilment model, with favourable unit economics being seen as prescription volumes continue to scale.

• Valuation suggests significant upside potential should forecasts be met We expect revenues and profits to grow rapidly in 2027, 2028 and 2029 after the bedding in year of 2026. Using our 2027 forecasts for revenues and net cash, an 8 times EV/revenue multiple and 20% discount rate, we derive a valuation of41.57p per share, which we choose to set as our updated target price

X

@investwisely123

#MPAL 41p+ price target

and link to document

From the last RNS

“ Our pharmacy dispensing infrastructure is a genuine differentiator as this market matures."

Depends if MPAL reveal a “healthy” waiting list like Chemist4U.

THE ‘game-changer’ Wegovy pill has been approved by the medicines regulator in a UK first.

But even before the GLP-1 tablet was greenlit for UK use, thousands of Brits joined pharmacy “waiting lists”, desperate to get their hands on the “miracle” drugs once they dropped.

Https://www.msn.com/en-gb/health/weightloss/wegovy-pill-weight-loss-drug-approved-for-use-in-britain-and-it-will-be-cheaper-than-injections/ar-AA25oMDl